DAWNRAYS PHARMA (02348) announced its interim results for 2025, reporting revenue of approximately RMB 630 million, representing a 9.2% year-on-year increase. Gross profit reached approximately RMB 314 million, declining 7.1% compared to the same period last year. Profit attributable to owners of the parent company totaled approximately RMB 105 million, marking a significant 78.79% decrease year-on-year. Earnings per share stood at RMB 0.06961, with an interim dividend of HKD 0.015 per share.
Breaking down product performance: The "An" series products for hypertension treatment experienced a 5.7% decline in sales volume and a 22.1% drop in sales revenue compared to the previous year, primarily attributed to price reductions in certain regions due to national centralized procurement policies. Entecavir dispersible tablets, an antiviral medication, demonstrated growth with sales volume increasing 14.0% and sales revenue rising 8.7% year-on-year. The Fujian Dongrui product series, primarily targeting hyperlipidemia treatment, showed strong performance with sales volume up 19.5% and sales revenue increasing 16.6% compared to the same period last year. Cephalosporin powder injections recorded substantial growth, with sales volume surging 47.9% and sales revenue climbing 55.7% year-on-year.
Following the successive commercial production launches at the company's wholly-owned subsidiaries - Suzhou Dongrui Pharmaceutical Co., Ltd.'s Shanfeng Road facility and Lanzhou Dongrui Pharmaceutical Co., Ltd. - intermediates and active pharmaceutical ingredients achieved remarkable growth, with sales volume increasing 244.8% and sales revenue rising 142.7% compared to 2024.
The company attributed the profit decline during this period to several factors: the Suzhou Dongrui Shanfeng Road facility and Lanzhou Dongrui have not yet achieved large-scale commercial production, price reductions in certain provinces for the "An" series and other centralized procurement products due to national policy impacts, and increased research and development expenses.